The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
|Articles|November 9, 2020
Pharmacy Times: Week of November 9 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Patrick Campbell, senior director of research at the Pharmacy Quality Alliance, about using text message video to increase primary medication adherence.
- A new episode of the Pharmacy Focus podcast which discusses how coronavirus disease 2019 (COVID-19) has affected cancer care with David Hughes, clinical pharmacy specialist in hematology and oncology at Boston Medical Center, and Radhika Jhaveri, clinical manager at Boston Medical Center who oversees infusion-based chemotherapy.
- On Wednesday, Pharmacy Times will publish an overview of the future for hospital pharmacies in the wake of the pandemic. The article examines how the COVID-19 crisis sparked an abrupt and intensive reevaluation of nearly every aspect of hospital pharmacy operations, from the logistics of drug procurement to the relationships that are so critical to delivering quality care.
Advertisement
Related to this article
Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Pharmacists make a difference in patients’ lives through MTM services.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Finerenone in Heart Failure: Evidence and Practice a Year Later
3
Researchers Target Viral Fusion for Universal Flu, HIV Vaccines
4
FDA Approves Zilucoplan Autoinjector for Myasthenia Gravis
5